
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand in the U.S.
Karsten Munk Knudsen, Novo Nordisk’s chief financial officer, told Fortune the company is well-placed to handle the geopolitical upheaval that rocked global business in March and April.